Clinical Trials

At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.

NOW ENROLLING

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 (tomivosertib) in Subjects With Hematological Malignancies

Disease:
Non-germinal center B cell diffuse large B cell lymphoma (Non-GCB DLBCL), including Activated B cell (ABC) DLBCL

Phase 2 study is now enrolling.

More Info Clinical Trial

A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy that are experiencing Insufficient Response to Checkpoint Inhibitor Alone

Disease:
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.

Phase 2 study is now enrolling.

More Info Clinical Trial

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Disease:
Microsatellite stable colorectal cancer (MSS CRC)

Phase 2 study enrollment is complete.

More Info Clinical Trial

A Phase 2 Non-randomized Open-label Study Examining the Effect of eFT508 in Patients with Advanced Castrate-Resistant Prostate Cancer (CRPC)

Disease:
Metastatic castration-resistant prostate cancer (mCRPC)

Phase 2 study is not yet enrolling.

More Info Clinical Trial

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subject with Hematological Malignancies

Disease:
Lymphoma

Phase 1 study not yet enrolling.

More Info